Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

We studied whether combinations of botanical extracts enriched in either Δ9‐tetrahydrocannabinol (Δ9‐THC) or cannabidiol (CBD), which are the main constituents of the cannabis‐based medicine Sativex, provide neuroprotection in rat models of Huntington's disease (HD). We used rats intoxicated wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuroscience research 2011-09, Vol.89 (9), p.1509-1518
Hauptverfasser:	Sagredo, Onintza, Pazos, M. Ruth, Satta, Valentina, Ramos, José A., Pertwee, Roger G., Fernández-Ruiz, Javier
Format:	Artikel
Sprache:	eng
Schlagworte:	3-Nitropropionic acid Animal models Animals Antagonists Antioxidants basal ganglia Calpain cannabidiol Cannabidiol - therapeutic use Cannabinoid CB1 receptors cannabinoid receptors Cannabinoids - therapeutic use Caudate Nucleus - cytology Caudate Nucleus - drug effects Cells, Cultured Clinical trials Disease Models, Animal Disease Progression Dronabinol - therapeutic use Drug Combinations gamma -Aminobutyric acid Huntington Disease - drug therapy Huntington Disease - pathology Huntington's disease Inflammation Insulin-like growth factor I Male malonate Neostriatum - drug effects Neostriatum - pathology Nervous system neurodegeneration Neurons Neuroprotection Neuroprotective agents Neuroprotective Agents - therapeutic use Nitric-oxide synthase phytocannabinoids Phytotherapy Plant Extracts - therapeutic use Putamen - cytology Putamen - drug effects Rats Rats, Sprague-Dawley Superoxide Δ9-tetrahydrocannabinol
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!